The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
